Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in persistent or chronic primary ITP
NCT05232149Phase 2Unknown
- Sponsor
- InnoCare Pharma
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in primary immune thrombocytopenia (ITP), sponsored by InnoCare Pharma. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05232149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232149.